These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36321611)

  • 1. Identification of RUNX1 and IFNGR2 as prognostic-related biomarkers correlated with immune infiltration and subtype differentiation of low-grade glioma.
    Zhang X; Chu H; Cheng Y; Ren J; Wang W; Liu X; Yan X
    Biomol Biomed; 2023 May; 23(3):405-425. PubMed ID: 36321611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
    Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
    Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.
    Lu Y; Chang P; Bian J; Zhu L
    Cancer Biomark; 2023; 38(3):393-407. PubMed ID: 37955080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
    Li J; Guo Q; Xing R
    BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
    Mou Y; Zhang L; Liu Z; Song X
    BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas.
    Trieu V; Maida AE; Qazi S
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
    Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
    Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 17. IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma.
    Peng S; Wang G; Cheng Z; Guo Z
    Int J Gen Med; 2021; 14():4381-4393. PubMed ID: 34413671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RUNX1/CD44 axis regulates the proliferation, migration, and immunotherapy of gliomas: A single-cell sequencing analysis.
    Zhang H; Cao H; Luo H; Zhang N; Wang Z; Dai Z; Wu W; Liu G; Xie Z; Cheng Q; Cheng Y
    Front Immunol; 2023; 14():1086280. PubMed ID: 36776876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IgG Fc binding protein (FCGBP) as a prognostic marker of low-grade glioma and its correlation analysis with immune infiltration].
    Liu Q; Zhang J; Zhang F; Zhang W; Gong L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Aug; 39(8):686-692. PubMed ID: 37515334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.